[18F]FLT-PET in oncology: current status and opportunities
In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this rev...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2004-12, Vol.31 (12), p.1659-1672 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1672 |
|---|---|
| container_issue | 12 |
| container_start_page | 1659 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 31 |
| creator | Been, Lukas B Suurmeijer, Albert J H Cobben, David C P Jager, Pieter L Hoekstra, Harald J Elsinga, Philip H |
| description | In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer. |
| doi_str_mv | 10.1007/s00259-004-1687-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67153977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67153977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-772b319284df11b011b2ff8002a8194ea1be55c3339d4ac7d5217a1d114a195c3</originalsourceid><addsrcrecordid>eNpdkMFLwzAUxoMobk7_AC9SPHiL5iVNk-wmY1OhoId5Eglpm0pH19SkPey_N2NDwcPjPXjf9_HxQ-gayD0QIh4CIZQrTEiKIZMCZydoChkoLIhUp7-3IBN0EcKGEJBUqnM0Ac4zzhhM0fwD5Opzla_x23KdNF3iutK17ms3T8rRe9sNSRjMMIbEdFXi-t75YeyaobHhEp3Vpg326rhn6H21XC-ecf769LJ4zHHJFB2wELRgoKhMqxqgIHFoXctY3UhQqTVQWM5LxpiqUlOKilMQBiqA1ICKjxm6O-T23n2PNgx624TStq3prBuDzgRwpoSIwtt_wo0bfRe7aQpplgLhNIrgICq9C8HbWve-2Rq_00D0nqo-UNWRqt5T1Vn03ByDx2Jrqz_HESP7AdSqb6w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214641052</pqid></control><display><type>article</type><title>[18F]FLT-PET in oncology: current status and opportunities</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Been, Lukas B ; Suurmeijer, Albert J H ; Cobben, David C P ; Jager, Pieter L ; Hoekstra, Harald J ; Elsinga, Philip H</creator><creatorcontrib>Been, Lukas B ; Suurmeijer, Albert J H ; Cobben, David C P ; Jager, Pieter L ; Hoekstra, Harald J ; Elsinga, Philip H</creatorcontrib><description>In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-004-1687-6</identifier><identifier>PMID: 15565331</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Animals ; Dideoxynucleosides ; Humans ; Neoplasm Invasiveness - diagnostic imaging ; Neoplasm Staging - methods ; Neoplasm Staging - trends ; Neoplasms - classification ; Neoplasms - diagnostic imaging ; Neoplasms - pathology ; Positron-Emission Tomography - methods ; Positron-Emission Tomography - trends ; Radiopharmaceuticals ; Severity of Illness Index</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2004-12, Vol.31 (12), p.1659-1672</ispartof><rights>Copyright Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-772b319284df11b011b2ff8002a8194ea1be55c3339d4ac7d5217a1d114a195c3</citedby><cites>FETCH-LOGICAL-c392t-772b319284df11b011b2ff8002a8194ea1be55c3339d4ac7d5217a1d114a195c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15565331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Been, Lukas B</creatorcontrib><creatorcontrib>Suurmeijer, Albert J H</creatorcontrib><creatorcontrib>Cobben, David C P</creatorcontrib><creatorcontrib>Jager, Pieter L</creatorcontrib><creatorcontrib>Hoekstra, Harald J</creatorcontrib><creatorcontrib>Elsinga, Philip H</creatorcontrib><title>[18F]FLT-PET in oncology: current status and opportunities</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer.</description><subject>Animals</subject><subject>Dideoxynucleosides</subject><subject>Humans</subject><subject>Neoplasm Invasiveness - diagnostic imaging</subject><subject>Neoplasm Staging - methods</subject><subject>Neoplasm Staging - trends</subject><subject>Neoplasms - classification</subject><subject>Neoplasms - diagnostic imaging</subject><subject>Neoplasms - pathology</subject><subject>Positron-Emission Tomography - methods</subject><subject>Positron-Emission Tomography - trends</subject><subject>Radiopharmaceuticals</subject><subject>Severity of Illness Index</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkMFLwzAUxoMobk7_AC9SPHiL5iVNk-wmY1OhoId5Eglpm0pH19SkPey_N2NDwcPjPXjf9_HxQ-gayD0QIh4CIZQrTEiKIZMCZydoChkoLIhUp7-3IBN0EcKGEJBUqnM0Ac4zzhhM0fwD5Opzla_x23KdNF3iutK17ms3T8rRe9sNSRjMMIbEdFXi-t75YeyaobHhEp3Vpg326rhn6H21XC-ecf769LJ4zHHJFB2wELRgoKhMqxqgIHFoXctY3UhQqTVQWM5LxpiqUlOKilMQBiqA1ICKjxm6O-T23n2PNgx624TStq3prBuDzgRwpoSIwtt_wo0bfRe7aQpplgLhNIrgICq9C8HbWve-2Rq_00D0nqo-UNWRqt5T1Vn03ByDx2Jrqz_HESP7AdSqb6w</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Been, Lukas B</creator><creator>Suurmeijer, Albert J H</creator><creator>Cobben, David C P</creator><creator>Jager, Pieter L</creator><creator>Hoekstra, Harald J</creator><creator>Elsinga, Philip H</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>[18F]FLT-PET in oncology: current status and opportunities</title><author>Been, Lukas B ; Suurmeijer, Albert J H ; Cobben, David C P ; Jager, Pieter L ; Hoekstra, Harald J ; Elsinga, Philip H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-772b319284df11b011b2ff8002a8194ea1be55c3339d4ac7d5217a1d114a195c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Dideoxynucleosides</topic><topic>Humans</topic><topic>Neoplasm Invasiveness - diagnostic imaging</topic><topic>Neoplasm Staging - methods</topic><topic>Neoplasm Staging - trends</topic><topic>Neoplasms - classification</topic><topic>Neoplasms - diagnostic imaging</topic><topic>Neoplasms - pathology</topic><topic>Positron-Emission Tomography - methods</topic><topic>Positron-Emission Tomography - trends</topic><topic>Radiopharmaceuticals</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Been, Lukas B</creatorcontrib><creatorcontrib>Suurmeijer, Albert J H</creatorcontrib><creatorcontrib>Cobben, David C P</creatorcontrib><creatorcontrib>Jager, Pieter L</creatorcontrib><creatorcontrib>Hoekstra, Harald J</creatorcontrib><creatorcontrib>Elsinga, Philip H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Been, Lukas B</au><au>Suurmeijer, Albert J H</au><au>Cobben, David C P</au><au>Jager, Pieter L</au><au>Hoekstra, Harald J</au><au>Elsinga, Philip H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[18F]FLT-PET in oncology: current status and opportunities</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>31</volume><issue>12</issue><spage>1659</spage><epage>1672</epage><pages>1659-1672</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>In recent years, [18F]-fluoro-3'-deoxy-3'-L: -fluorothymidine ([18F]FLT) has been developed as a proliferation tracer. Imaging and measurement of proliferation with PET could provide us with a non-invasive staging tool and a tool to monitor the response to anticancer treatment. In this review, the basis of [18F]FLT as a proliferation tracer is discussed. Furthermore, an overview of the current status of [18F]FLT-PET research is given. The results of this research show that although [18F]FLT is a tracer that visualises cellular proliferation, it also has certain limitations. In comparison with the most widely used PET tracer, [18F]FDG, [18F]FLT uptake is lower in most cases. Furthermore, [18F]FLT uptake does not always reflect the tumour cell proliferation rate, for example during or shortly after certain chemotherapy regimens. The opportunities provided by, and the limitations of, [18F]FLT as a proliferation tracer are addressed in this review, and directions are given for further research, taking into account the strong and weak points of the new tracer.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>15565331</pmid><doi>10.1007/s00259-004-1687-6</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2004-12, Vol.31 (12), p.1659-1672 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67153977 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Dideoxynucleosides Humans Neoplasm Invasiveness - diagnostic imaging Neoplasm Staging - methods Neoplasm Staging - trends Neoplasms - classification Neoplasms - diagnostic imaging Neoplasms - pathology Positron-Emission Tomography - methods Positron-Emission Tomography - trends Radiopharmaceuticals Severity of Illness Index |
| title | [18F]FLT-PET in oncology: current status and opportunities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A08%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B18F%5DFLT-PET%20in%20oncology:%20current%20status%20and%20opportunities&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Been,%20Lukas%20B&rft.date=2004-12-01&rft.volume=31&rft.issue=12&rft.spage=1659&rft.epage=1672&rft.pages=1659-1672&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-004-1687-6&rft_dat=%3Cproquest_cross%3E67153977%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214641052&rft_id=info:pmid/15565331&rfr_iscdi=true |